Facedrive Provides Update on Facedrive Foods’ Revenue and Expenses
TORONTO–(BUSINESS WIRE)–#FacedriveScarborough–Facedrive Inc. (“Facedrive” or the “Company”) (TSXV:FD), (OTC:FDVRF), a Canadian “people-and-planet first” tech ecosystem…
TORONTO–(BUSINESS WIRE)–#FacedriveScarborough–Facedrive Inc. (“Facedrive” or the “Company”) (TSXV:FD), (OTC:FDVRF), a Canadian “people-and-planet first” tech ecosystem…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed…
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta…
Publication demonstrates FDA cleared Acuitas AMR Gene Panel detects and differentiates a broad range of…
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS),…
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company…
Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2…
– Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization…
AUSTIN, Texas, Feb. 10, 2022 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage…
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX,…
HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
– Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing…
LungFit® PH premarket approval (PMA) submission under active review by U.S. FDA; approval and commercial…
REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq:CDXS), a leading enzyme…
COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced…
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE),…
Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision…
Edmonton, Alberta–(Newsfile Corp. – February 10, 2022) – Titan Logix Corp., (TSXV: TLA) (“Titan” or…
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…